Bio Pharma Dive
OCTOBER 27, 2020
The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.
World of DTC Marketing
OCTOBER 27, 2020
We keep hearing the term “consumers of health” but the American healthcare system is too profitable to allow people to be consumers of healthcare. “The need for action now is clear. Health care costs are climbing so fast they may soon threaten the quality of care and access to care which Americans enjoy.” Ronald Reagan. What if … people got a fair ROI for healthcare spending the way we expect a reasonable return from other investments?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 27, 2020
Learn about strategies for identifying and recruiting rare disease patients.
BioSpace
OCTOBER 27, 2020
South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
OCTOBER 27, 2020
The deal, worth up to $2.15 billion, comes weeks after Illumina agreed to pay $8 billion to acquire liquid biopsy developer Grail.
BioSpace
OCTOBER 27, 2020
The report showed that in some cases, people who have recovered from the virus continued to exhibit significant cognitive deficits.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 27, 2020
Analysing real-world health data could help overcome the bias towards men in traditional medical research, says Sensyne Health’s Dr Lucy Mackillop. Collecting and analysing anonymised patient data has the potential to generate valuable insights that can catalyse research, lead to improved patient care, and power the development of new treatments.
BioSpace
OCTOBER 27, 2020
The number of excess deaths in the United States is trending downward despite autumn upticks in COVID-19 incidents.
XTalks
OCTOBER 27, 2020
In recent years, food companies have created products that go beyond taste and convenience and also offer functionality and health benefits. Now, beverages are starting to offer the same advantages. These beverages are categorized in the industry as “fusion beverages,” and offer consumers more than just a way to quench their thirst. One such fusion beverage is high-protein iced tea – a functional, refreshing beverage that has the potential to be the next big beverage trend.
BioPharma Reporter
OCTOBER 27, 2020
Novavaxâs Phase 3 COVID-19 vaccine trial in the UK has been expanded to 15,000 participants; while a 30,000 strong Phase 3 clinical trial is due to start in the US and Mexico next month.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 27, 2020
Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to date suggest it is unlikely to be effective. The ACTIV-3 study was comparing bamlanivimab (also known as LY-CoV555 or LY3819253) and placebo when added to therapy with Gilead Sciences’ Veklury (remdesivir), which is already approved to treat COVID-19 requiring hospitalisation.
BioSpace
OCTOBER 27, 2020
Pfizer indicated yesterday that its Phase III clinical trial of 44,000 volunteers now needs fewer than 2,000 people to be fully enrolled.
Scienmag
OCTOBER 27, 2020
Modeling shows SARS-CoV2 isn’t spread very well by the small droplets that linger longest Credit: University of Amsterdam WASHINGTON, October 27, 2020 — Aerosol microdroplets, the tiny particles that linger in the air longest after we talk, cough, or sneeze, do not appear to be extremely efficient at spreading the virus that leads to COVID-19. […].
BioSpace
OCTOBER 27, 2020
The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Scienmag
OCTOBER 27, 2020
How to design organic solar cell materials Credit: MPI-P Most of us are familiar with silicon solar cells, which can be found on the rooftops of modern houses. These cells are made of two silicon layers, which contain different atoms such as boron and phosphorus. When combined, these layers direct charges generated by the absorbed […].
pharmaphorum
OCTOBER 27, 2020
US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Shares in the company plunged more than 40% on the Nasdaq after the announcement, which revealed a difference in survival rates between the two groups enrolled into the study.
Scienmag
OCTOBER 27, 2020
The finding provides a basis for Credit: UPF and CNIC Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age. This study presents the results […].
BioSpace
OCTOBER 27, 2020
Chasity’s story stands in hopeful defiance of a typically grim acute lymphocytic leukemia prognosis. In this case, CAR T cell therapy has proven to be a uniquely viable option.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
OCTOBER 27, 2020
UC Riverside-led study describes first published survey documenting nature and extent of caregiver mistreatment of this population Credit: Stan Lim, UC Riverside. Four in 10 people with advanced multiple sclerosis, or MS, are emotionally abused by someone responsible for caring for them, reports a study led by the University of California, Riverside.
BioPharma Reporter
OCTOBER 27, 2020
Thermo Fisher Scientific is seeing âvery, very significant demandâ for its cold storage range as the race to get COVID-19 vaccines to market enters its closing stages.
Scienmag
OCTOBER 27, 2020
Deep Longevity added SquareOne Wellness to its growing longevity network; SquareOne physicians will get training in longevity medicine and interpret the AgeMetric™ reports incorporating multiple aging clocks Credit: © Deep Longevity, Inc Today, Deep Longevity Inc, a pioneer in deep biomarkers of aging and longevity, and SquareOne Wellness announced a collaboration to deploy an extensive […].
BioSpace
OCTOBER 27, 2020
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
OCTOBER 27, 2020
Credit: Daniel Vegel Living organisms aren’t the only things that evolve over time. Cultural practices change, too, and in recent years social scientists have taken a keen interest in understanding this cultural evolution. Much research has focused on psychological factors among individuals, like how our visual system constrains the shape of written characters.
BioSpace
OCTOBER 27, 2020
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Intouch Solutions
OCTOBER 27, 2020
NEW YORK, NY (October 27, 2020) Intouch Media announced it has released a new whitepaper, “Future State: The New Media Landscape,” that explores and provides guidance on four critical media industry trends -- the rise of automatic content recognition, addressable TV, privacy versus personalization and the cookieless future. Intouch Media, in conjunction with media analyst firm.
Scienmag
OCTOBER 27, 2020
Building the driving machinery of bacteria, the flagella, requires numerous proteins to be assembled. Adding sugar and the presence of a control point are two key steps identified by UNIGE scientists. Credit: UNIGE/VIOLLIER To build the machinery that enables bacteria to swim, over 50 proteins have to be assembled according to a logic and well-defined […].
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
OCTOBER 27, 2020
The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.
Scienmag
OCTOBER 27, 2020
Lehigh University professor and researcher recognized by prestigious academic journal Credit: Lehigh University Himanshu Jain, Lehigh University’s T.L. Diamond Distinguished Chair in Engineering and Applied Science and Professor of Materials Science and Engineering, has been named as the winner of the 2020 N.F Mott Award, among the most prestigious in the field of glass science. […].
pharmaphorum
OCTOBER 27, 2020
Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company has had to weather lower revenues for the third quarter due to the ongoing impacts of COVID-19. Despite the decline, biopharma revenues increased overall. Total third-quarter 2020 revenues hit $12.1 billion, a decrease of $549 million, or 4%, compared to last year.
BioSpace
OCTOBER 27, 2020
A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
267 
Let's personalize your content